Lion Biotechnologies Inc (LBIO)

7.95
0.05 0.62
NASDAQ : Health Care
Prev Close 8.00
Open 8.05
Day Low/High 7.70 / 8.05
52 Wk Low/High 4.45 / 8.60
Volume 347.20K
Avg Volume 427.00K
Exchange NASDAQ
Shares Outstanding 62.35M
Market Cap 433.34M
EPS -3.50
P/E Ratio N/A
Div & Yield N.A. (N.A)
'Mad Money' Lightning Round: I'm Staying Away From Five Below

'Mad Money' Lightning Round: I'm Staying Away From Five Below

Cramer isn't crazy about Dicerna Pharmaceuticals and Ziopharm Oncology but he likes Akamai and Lion Biotechnologies.

Jim Cramer's 'Mad Money' Recap: The Fed Does the Right Thing

Jim Cramer's 'Mad Money' Recap: The Fed Does the Right Thing

The Federal Reserve is smarter than you think, Cramer says.

Machines Drive the Action

Today had nothing to do with fundamentals.

Biotechs Enliven Familiar Pattern

Buying was more sedate than it has been.

Nasdaq 5000 Is Meaningless

Stay focused on price and remember that the market's riding a trend.

Lion Biotechnologies Obtains Exclusive License From NIH For Next-Generation TIL Technology

Lion Biotechnologies Obtains Exclusive License From NIH For Next-Generation TIL Technology

Novel Method Enhances Quality and Efficiency of TIL Production

Lion Biotechnologies CSO Laszlo Radvanyi Co-authors Study In Clinical Cancer Research

Lion Biotechnologies CSO Laszlo Radvanyi Co-authors Study In Clinical Cancer Research

Research Validates Method for Enhancing Quality and Efficiency of TIL Production

Lion Biotechnologies Announces Positive New Data From Lead TIL Melanoma Program At ASH

Lion Biotechnologies Announces Positive New Data From Lead TIL Melanoma Program At ASH

TILs Demonstrate 54% Objective Response Rate in Phase 2 Metastatic Melanoma Trial

Lion Biotechnologies Announces Clinical Data Update At American Society Of Hematology Annual Meeting

Lion Biotechnologies Announces Clinical Data Update At American Society Of Hematology Annual Meeting

NCI's Dr. Steven Rosenberg to Present New TIL Trial Data in Scientific Symposium

Lion Biotechnologies Announces Management Change

Lion Biotechnologies Announces Management Change

Company Remains on Track to Achieve Strategic Objectives

Lion Biotechnologies CSO Laszlo Radvanyi Co-Authors Study In Journal Of Immunotherapy

Lion Biotechnologies CSO Laszlo Radvanyi Co-Authors Study In Journal Of Immunotherapy

Research Validates More Practical, Cost-Efficient Method for TIL Manufacturing

Lion Biotechnologies' Chief Scientific Officer To Present At Immunotherapies And Vaccines Summit

Lion Biotechnologies' Chief Scientific Officer To Present At Immunotherapies And Vaccines Summit

Laszlo Radvanyi to Join Key Discussions on Cancer Immunotherapies

Lion Biotechnologies Enters Clinical Trial Grant Agreement With Moffitt Cancer Center

Lion Biotechnologies Enters Clinical Trial Grant Agreement With Moffitt Cancer Center

Grant to Fund Expanded Study of TIL Therapy With Ipilimumab